Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Boehringer Ingelheim
AstraZeneca
Baxter
Colorcon

Last Updated: July 3, 2022

Amryt Company Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Amryt
International Patents:80
US Patents:16
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Amryt

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amryt MYCAPSSA octreotide acetate CAPSULE, DELAYED RELEASE;ORAL 208232-001 Jun 26, 2020 RX Yes Yes 11,052,126 See Plans and Pricing See Plans and Pricing
Amryt JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-005 Apr 23, 2015 DISCN Yes No 9,364,470 See Plans and Pricing See Plans and Pricing
Amryt JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-001 Dec 21, 2012 RX Yes No 8,618,135 See Plans and Pricing See Plans and Pricing
Amryt MYCAPSSA octreotide acetate CAPSULE, DELAYED RELEASE;ORAL 208232-001 Jun 26, 2020 RX Yes Yes 10,238,709 See Plans and Pricing See Plans and Pricing
Amryt JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-005 Apr 23, 2015 DISCN Yes No 9,433,617 See Plans and Pricing See Plans and Pricing
Amryt JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-002 Dec 21, 2012 RX Yes No 9,364,470 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Amryt

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Amryt JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-005 Apr 23, 2015 5,712,279 See Plans and Pricing
Amryt JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-001 Dec 21, 2012 5,712,279 See Plans and Pricing
Amryt JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-002 Dec 21, 2012 6,492,365 See Plans and Pricing
Amryt JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-005 Apr 23, 2015 6,492,365 See Plans and Pricing
Amryt JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-001 Dec 21, 2012 6,492,365 See Plans and Pricing
Amryt JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-003 Dec 21, 2012 6,492,365 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Amryt Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1725234 14C0003 France See Plans and Pricing PRODUCT NAME: LOMITAPIDE , OU UN SEL PHARMACEUTIQUEMENT ACTIF DE CELUI-CI.; REGISTRATION NO/DATE: EU/1/13/851/001 20130805
1725234 PA2014001,C1725234 Lithuania See Plans and Pricing PRODUCT NAME: LOMITAPIDAS; REGISTRATION NO/DATE: EU/1/13/851/001, 2013-07-31 EU/1/13/851/002, 2013-07-31 EU/1/13/851/003 20130731
1725234 C20140001 00107 Estonia See Plans and Pricing PRODUCT NAME: LOMITAPIID;REG NO/DATE: K(2013)5153(LOPLIK) 05.08.2013
1725234 2013/063 Ireland See Plans and Pricing PRODUCT NAME: LOMITAPIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130731
1725234 498 Finland See Plans and Pricing
1725234 206 5001-2014 Slovakia See Plans and Pricing PRODUCT NAME: LOMITAPID; REGISTRATION NO/DATE: EU/1/13/851/001 - EU/1/13/851/003 20130805
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Express Scripts
McKinsey
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.